Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have earned a consensus rating of “Moderate Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $20.3333.

A number of equities research analysts recently commented on the company. JPMorgan Chase & Co. started coverage on Enanta Pharmaceuticals in a research note on Friday, November 14th. They set an “overweight” rating and a $17.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Wednesday, January 21st. Finally, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, February 10th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Seven Fleet Capital Management LP acquired a new position in Enanta Pharmaceuticals during the fourth quarter valued at approximately $36,000. Virtu Financial LLC acquired a new stake in Enanta Pharmaceuticals in the fourth quarter worth $220,000. Invesco Ltd. boosted its position in shares of Enanta Pharmaceuticals by 325.2% during the fourth quarter. Invesco Ltd. now owns 253,811 shares of the biotechnology company’s stock worth $4,003,000 after purchasing an additional 194,113 shares in the last quarter. Krensavage Asset Management LLC boosted its position in shares of Enanta Pharmaceuticals by 30.8% during the fourth quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock worth $43,626,000 after purchasing an additional 651,946 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new position in shares of Enanta Pharmaceuticals in the 4th quarter valued at $997,000. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA stock opened at $13.54 on Monday. The firm’s 50 day moving average price is $13.78 and its two-hundred day moving average price is $12.22. Enanta Pharmaceuticals has a 52-week low of $4.09 and a 52-week high of $17.15. The stock has a market cap of $392.93 million, a PE ratio of -4.23 and a beta of 0.95.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, February 9th. The biotechnology company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.12. The company had revenue of $18.62 million during the quarter, compared to analysts’ expectations of $16.14 million. Enanta Pharmaceuticals had a negative net margin of 106.80% and a negative return on equity of 78.58%. As a group, sell-side analysts predict that Enanta Pharmaceuticals will post -4.65 earnings per share for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.